65th ASH Annual Meeting & Exposition

• Include: 262 videos + 1193 pdfs, size: 96.7 GB

 Topics:

Education Program Acquired Hemophilia A Diagnosis and Management Andreas Tiede-24122.pdf
Education Program Acquired Hemophilia A Diagnosis and Management Rebecca Kruse-Jarres-24122.pdf
Education Program Acquired Hemophilia A Diagnosis and Management Sean Platton-24122.pdf
Education Program Acquired Hemophilia A Diagnosis and Management.ts
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Ashish Kumar-24117.pdf
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Clifford Takemoto-24117.pdf
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Nicole Kucine-24117.pdf
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units.ts
Education Program Are We Personalizing MDS Therapy in 2023 David Sallman-24106.pdf
Education Program Are We Personalizing MDS Therapy in 2023 Marie Sebert-24106.pdf
Education Program Are We Personalizing MDS Therapy in 2023 Rena Xian-24106.pdf
Education Program Are We Personalizing MDS Therapy in 2023.ts
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Alice Bertaina-24107.pdf
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Nirali Shah-24107.pdf
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Stephen Gottschalk-24107.pdf
Education Program CAR T Cells in ALL Bridge or Definitive Therapy.ts
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Eduard Van Beers-24125.pdf
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Kevin Kuo-24125.pdf
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Rachael Grace-24125.pdf
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias.ts
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kasiani Myers-24118.pdf
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kristen Schratz-24118.pdf
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Suneet Agarwal-24118.pdf
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right.ts
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Idoroenyi Amanam-24100.pdf
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Kirk Schultz-24100.pdf
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Muna Qayed-24100.pdf
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure.ts
Education Program Have We Optimized Therapy Yet for Patients with AML Justin Watts-24104.pdf
Education Program Have We Optimized Therapy Yet for Patients with AML Tara Lin-24104.pdf
Education Program Have We Optimized Therapy Yet for Patients with AML.ts
Education Program Hematologic Toxicity of Immunotherapies Frederick Locke-24113.pdf
Education Program Hematologic Toxicity of Immunotherapies Martin Hutchings-24113.pdf
Education Program Hematologic Toxicity of Immunotherapies Michael Kroll-24113.pdf
Education Program Hematologic Toxicity of Immunotherapies.ts
Education Program Hematologists and the Care of Pregnant Women Adam Lewkowitz-24121.pdf
Education Program Hematologists and the Care of Pregnant Women Andra James-24121.pdf
Education Program Hematologists and the Care of Pregnant Women Fionnuala Ni Ainle-24121.pdf
Education Program Hematologists and the Care of Pregnant Women.ts
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Adi Zoref-Lorenz-24124.pdf
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Martin Tallman-24124.pdf
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Steven Fein-24124.pdf
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies.ts
Education Program Hemostasis in Patients With Severe Liver Disease Lara Roberts-24123.pdf
Education Program Hemostasis in Patients With Severe Liver Disease Ton Lisman-24123.pdf
Education Program Hemostasis in Patients With Severe Liver Disease Walter Ageno-24123.pdf
Education Program Hemostasis in Patients With Severe Liver Disease.ts
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Darja Karpova-24119.pdf
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Mindy Goldman-24119.pdf
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Richard Kaufman-24119.pdf
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice.ts
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Dipti Patel-Donnelly-24110.pdf
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Jesus Berdeja-24110.pdf
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Ruemu Birhiray-24110.pdf
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community.ts
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Nizar Bahlis-24102.pdf
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Sham Mailankody-24102.pdf
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Surbhi Sidana-24102.pdf
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies.ts
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Anna Maria Sureda Balari-24097.pdf
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Loretta Nastoupil-24097.pdf
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Manali Kamdar-24097.pdf
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023.ts
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Anita DSouza-24112.pdf
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Deepti Radia-24112.pdf
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Oussama Abla-24112.pdf
Education Program How Do We Enhance Results in Rare Hematologic Malignancies.ts
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Chaitra Ujjani-24111.pdf
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Joanna Rhodes-24111.pdf
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Toby Eyre-24111.pdf
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023.ts
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Adam Cohen-24103.pdf
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Francesca Gay-24103.pdf
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Monique Hartley-Brown-24103.pdf
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023.ts
Education Program How Do We Tackle Remaining Clinical Challenges in CML Massimo Breccia-24109.pdf
Education Program How Do We Tackle Remaining Clinical Challenges in CML Naranie Shanmuganathan-24109.pdf
Education Program How Do We Tackle Remaining Clinical Challenges in CML Simona Soverini-24109.pdf
Education Program How Do We Tackle Remaining Clinical Challenges in CML.ts
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Andrew Evens-24098.pdf
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Natalie Grover-24098.pdf
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Sairah Ahmed-24098.pdf
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023.ts
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Adetola Kassim-24127.pdf
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle John Tisdale-24127.pdf
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Kenneth Ataga-24127.pdf
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle.ts
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Emma Groarke-24126.pdf
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Marena Niewisch-24126.pdf
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Timothy Olson-24126.pdf
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult.ts
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Emily Curran-24108.pdf
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL John Molina-24108.pdf
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Tamara Miller-24108.pdf
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL.ts
Education Program Ongoing Challenges in the Management of VTE Cecilia Becattini-24115.pdf
Education Program Ongoing Challenges in the Management of VTE Keith McCrae-24115.pdf
Education Program Ongoing Challenges in the Management of VTE Kenneth Bauer-24115.pdf
Education Program Ongoing Challenges in the Management of VTE.ts
Education Program The Iron Revolution Jacquelyn Powers-24116.pdf
Education Program The Iron Revolution Michael Auerbach-24116.pdf
Education Program The Iron Revolution Thomas Deloughery-24116.pdf
Education Program The Iron Revolution.ts
Education Program Transfusion Support in Sickle Cell Disease Anoosha Habibi-24120.pdf
Education Program Transfusion Support in Sickle Cell Disease France Pirenne-24120.pdf
Education Program Transfusion Support in Sickle Cell Disease Shannon Kelly-24120.pdf
Education Program Transfusion Support in Sickle Cell Disease.ts
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Douglas Tremblay-24099.pdf
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Harinder Gill-24099.pdf
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Jeanne Palmer-24099.pdf
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management.ts
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Alison Walker-24105.pdf
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Jacqueline Cloos-24105.pdf
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Marion Subklewe-24105.pdf
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML.ts
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Asmita Mishra-24101.pdf
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Reena Jayani-24101.pdf
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Roni Shouval-24101.pdf
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together.ts
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Jennifer McIntosh-24114.pdf
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Shruti Chaturvedi-24114.pdf
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies TBD Retter-24114.pdf
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies.ts
General Sessions ASH-EHA Joint Symposium Alexander Medvinsky-24135.pdf
General Sessions ASH-EHA Joint Symposium Linheng Li-24135.pdf
General Sessions ASH-EHA Joint Symposium.ts
General Sessions E. Donnall Thomas Lecture and Prize Katayoun Rezvani-24174.pdf
General Sessions E. Donnall Thomas Lecture and Prize.ts
General Sessions Ernest Beutler Lecture and Prize Johnny Mahlangu-24175.pdf
General Sessions Ernest Beutler Lecture and Prize Takehisa Kitazawa-24175.pdf
General Sessions Ernest Beutler Lecture and Prize.ts
General Sessions Ham-Wasserman Lecture Andreas Greinacher-24133.pdf
General Sessions Ham-Wasserman Lecture.ts
General Sessions Late Breaking Abstracts Adetola Kassim-25508.pdf
General Sessions Late Breaking Abstracts Hamish Scott-25508.pdf
General Sessions Late Breaking Abstracts Ibrahim Aldoss-25508.pdf
General Sessions Late Breaking Abstracts Keith McCrae-25508.pdf
General Sessions Late Breaking Abstracts Michael Wang-25508.pdf
General Sessions Late Breaking Abstracts Pieter Sonneveld-25508.pdf
General Sessions Late Breaking Abstracts.ts
General Sessions Plenary Scientific Session Banu Aygun-25390.pdf
General Sessions Plenary Scientific Session Betty Pace-25390.pdf
General Sessions Plenary Scientific Session Brian Krum-25390.pdf
General Sessions Plenary Scientific Session Daniel Wolff-25390.pdf
General Sessions Plenary Scientific Session Francesca Gay-25390.pdf
General Sessions Plenary Scientific Session Isaac Odame-25390.pdf
General Sessions Plenary Scientific Session Pamela Ting-25390.pdf
General Sessions Plenary Scientific Session Peter Voorhees-25390.pdf
General Sessions Plenary Scientific Session Salima Benbarche-25390.pdf
General Sessions Plenary Scientific Session Stefanie Sarantopoulos-25390.pdf
General Sessions Plenary Scientific Session Stephanie Halene-25390.pdf
General Sessions Plenary Scientific Session Trista North-25390.pdf
General Sessions Plenary Scientific Session.ts
General Sessions Presidential Symposium Claudia Kemper-24134.pdf
General Sessions Presidential Symposium Eleni Gavriilaki-24134.pdf
General Sessions Presidential Symposium Lubka Roumenina-24134.pdf
General Sessions Presidential Symposium.ts
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Hsiang-Ying Lee-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Lei Yu-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Marlies Rossmann-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Meng Zhang-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Vincent Schulz-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Xiurui Lv-24504.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation.ts
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rajesh Gunage-24503.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rebecca Griffiths-24503.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Xu Han-24503.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yajing Chu-24503.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yuefeng Tang-24503.pdf
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease.ts
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Caroline Philpott-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Gayle Ross-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Ilona Kleine Budde-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Rachel Josselsohn-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Tomas Ganz-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Veena Sangkhae-24505.pdf
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis.ts
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Alfonso Fernandez-24506.pdf
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Eugene Khandros-24506.pdf
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Ginette Balbin-Cuesta-24506.pdf
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Pinyaphat Khamphikham-24506.pdf
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Yu Wang-24506.pdf
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia.ts
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Auria Godard-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Boya Liu-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Britney Hernandez-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Luisanna Sanchez Ventura-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Mira Pochron-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Scott Peslak-24507.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease.ts
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Anton Ilich-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Christopher Chambliss-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Jason Sutin-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Malgorzata Kasztan-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Marissa Traets-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Suruchi Salgar-24508.pdf
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans.ts
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Alan Anderson-24511.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Angela Rankine-Mullings-24511.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Pablo Pelinski-24511.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Robyn Cohen-24511.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Sophie Lanzkron-24511.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation.ts
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Miguel Abboud-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Modupe Idowu-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Nirmish Shah-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Santosh Saraf-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Shubaya Naggayi-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Swee Lay Thein-24512.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease.ts
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Anna Sowa-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Dunia Hatabah-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Julie Kanter-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mariane De Montalembert-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mehndi Dandwani-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Modupe Idowu-24509.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors.ts
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Clare Zarka-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Jackie Queen-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Justin Yoo-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Kristine Karkoska-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Martha Kenney-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Ryan Sun-24510.pdf
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future.ts
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Adi Zoref-Lorenz-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Chen Li-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Coralie Bloch-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Misato Komori-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Ningning Zhang-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Peter Dimitrion-24514.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes.ts
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Christina Simoglou Karali-24513.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Danielle Arnold-24513.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Malte Ritter-24513.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Vahagn Makaryan-24513.pdf
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias.ts
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Benjamin Babcock-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Carlos Bravo-Perez-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Dandan Wang-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Francesco Saettini-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Mei Yu-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Melissa Mavers-24515.pdf
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity.ts
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Anish Sharda-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Huichun Zhan-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Junmei Chen-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Kelsey Sack-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Luke Dunaway-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Nilesh Pandey-24518.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis.ts
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Adam Kanack-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Caitlin Schneider-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Cristobal Rivera-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Meghna Naik-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Moua Yang-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Yvonne Kong-24517.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis.ts
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Anthony Washington-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Harvey Roweth-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Heng Mei-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Jianlin Qiao-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Lauren Murphy-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Yuxiu Chen-24516.pdf
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias.ts
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Ahmad Tarawah-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anna Frandsen-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anne Juhl-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes David Kuter-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Elizabeth King-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Hanny Al-Samkari-24521.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes.ts
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Catherine Broome-24519.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Michael Tarantino-24519.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Min Xu-24519.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Nichola Cooper-24519.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Yun Wang-24519.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia.ts
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Bertrand Godeau-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Cy Wilkins-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Etienne Crickx-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Taylor Kim-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yoann Zadro-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yuxiu Chen-24520.pdf
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations.ts
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Aleksandr Shamanaev-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Lucas Van Gorder-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Meng-Ni Fan-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Shekhar Kumar-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Thomas Girard-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Wenjing Cao-24522.pdf
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies.ts
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Davide Matino-24525.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Evelien Krumb-24525.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Guy Young-24525.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Marilyn Manco-Johnson-24525.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Yeu-Chin Chen-24525.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care.ts
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Allison Wheeler-24523.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Ferdows Atiq-24523.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Lynn Malec-24523.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Steven Pipe-24523.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan.ts
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Aditi Sharma-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Anthony Chan-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Ellen Zhang-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Eva Leinoe-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Rachel Kronenfeld-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Valentina Restrepo-24524.pdf
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders.ts
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Kenki Saito-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marie Scully-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marissa Schraner-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Maryam Subhan-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Omid Peyvandi-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Senthil Sukumar-24526.pdf
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations.ts
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Bec.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Jus.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Kri.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care She.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Sim.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care.ts
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Amelia Haj-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Gary Woods-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Julie Jaffray-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Justine Ryu-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Sacha Belinda Mapombo Choupa-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Vilmarie Rodriguez-24528.pdf
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism.ts
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Lise McQuilten-24529.pdf
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Matthew Tanner-24529.pdf
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Nanyan Zhang-24529.pdf
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Patricia Davenport-24529.pdf
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Slim Azouzi-24529.pdf
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine.ts
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alejandro Roisman-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alison Livada-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Helen Wang-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Stephanie Hurwitz-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Takao Yogo-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Tanner Martinez-24781.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness.ts
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Aditya Barve-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Karolina Vanickova-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Maegan Capitano-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Md Akram Hossain-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Virginia Camacho-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Yiran Meng-24530.pdf
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress.ts
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Lynn Quek-24532.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Nikolaos Sousos-24532.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Saravanan Ganesan-24532.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Sean Wen-24532.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries.ts
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Adriana Chiaramida-24531.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations J. Beeler-24531.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Johannes Damm-24531.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Nicole Prutsch-24531.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Yifan Zhou-24531.pdf
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations.ts
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Charles Ayemoba-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Dinisha Kamble-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Eman Khatib-Massalha-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Irene Ganan-Gomez-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Rheanna Congdon-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Shoichiro Takeishi-24533.pdf
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease.ts
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Bhavisha Patel-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carlos Bravo-Perez-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carmelo Gurnari-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Masanori Yoshida-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Pedro Prata-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Yoshitaka Zaimoku-24535.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment.ts
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Antonio Risitano-24534.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Austin Kulasekararaj-24534.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Carlos de Castro-24534.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Fengkui Zhang-24534.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Jens Panse-24534.pdf
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials.ts
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc .Kendra Jackson-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Johan Flygare-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Mona M.Hosseini-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Seth Rotz-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Valeria Visconte-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Y. Lucy Liu-24536.pdf
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc..ts
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Bac Viet Le-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Chun-Wei Chen-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Qingyu Luo-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Thomas Koehnke-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xiangguo Shi-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xin He-24538.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells.ts
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Ayana Kon-24537.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Cailin Collins-24537.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jane Xu-24537.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jie Bai-24537.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jonny Mendoza-Castrejon-24537.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy.ts
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Dorien Pastoors-24539.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Luca Nunzio Cifarelli-24539.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Madeline Niederkorn-24539.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Prajwal Boddu-24539.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Yu-Hsuan Chang-24539.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics.ts
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Amanda Tajik-24540.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Cl‚ment Larrue-24540.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Daiki Karigane-24540.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Junya Sango-24540.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Sarah Skuli-24540.pdf
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms.ts
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Darko Barisic-24541.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Gabriel Brisou-24541.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Mirca Saurty-Seerunghen-24541.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Ruifeng Sun-24541.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Sergio Roa-24541.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis.ts
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression I-Jun Lau-24542.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Marta Fernandes-24542.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Nataly Cruz-Rodriguez-24542.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Qi Jin-24542.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Vera Poort-24542.pdf
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression.ts
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Claudia Cabrera-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Eric Vick-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Karanpreet Bhatia-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Lei Zhang-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Sana Chaudhry-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Tim Kong-24545.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies.ts
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Kedwin Ventura-24543.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Li Du-24543.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Priyanka Sharma-24543.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Satoshi Kaito-24543.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Zhixiang Chen-24543.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies.ts
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Anagha Sheth-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Juan Jose Rodriguez Sevilla-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Vincent Rondeau-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Xinyue Zhou-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yi Zhang-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yuki Nishida-24544.pdf
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies.ts
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Damian Green-24546.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Keito Suto-24546.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Leandro Cerchietti-24546.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Nathan Beals-24546.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Selina Chen-Kiang-24546.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma.ts
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Britten Gordon-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Giulia Veltri-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Gregory Crimmins-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Jasmeet Sidhu-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Qin Li-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Thomas Lew-24547.pdf
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias.ts
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Aman Wadhwa-24548.pdf
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Motohiro Kato-24548.pdf
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Noam Kopmar-24548.pdf
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Sarah Elitzur-24548.pdf
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Stuart Winter-24548.pdf
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL.ts
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Curtis Lachowiez-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Enrico Attardi-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Pinkal Desai-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Rabea Mecklenbrauck-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Vikram Dhillon-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Wajma Shahbaz-24549.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related.ts
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Erika Cattaneo-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Georgina Gener-Ricos-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Himachandana Atluri-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Matthew Schwede-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Riya Sinha-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Xin Wang-24550.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI.ts
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Alex Bataller-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Constance Baer-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Marius Bill-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Niek Van Der Maas-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Richard Aplenc-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Yazan Abu-Shihab-24551.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication.ts
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Cameron Hunter-24552.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches David Grinblatt-24552.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches James Foran-24552.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Talha Badar-24552.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Zofia Gross-24552.pdf
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches.ts
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jayastu Jain-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jonathan Webster-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Marlise Luskin-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicola Goekbuget-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicolas Boissel-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Wanda Salzer-24554.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL.ts
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Karen Rabin-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Martin Schrappe-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Nicola Goekbuget-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Sabina Chiaretti-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Tanja Gruber-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Xiaoyuan Gong-24553.pdf
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL.ts
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML B. Smith-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Harry Erba-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Himachandana Atluri-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Hunault-Berger Mathilde-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Jing Lu-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Xiaohui Suo-24555.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML.ts
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Andrew Moore-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Fabio Guolo-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Franco Locatelli-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Kristoffer Hellstrand-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Li Gao-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Luca Guarnera-24557.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL.ts
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexander Perl-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexandre Kadia-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Gertjan Kaspers-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Nigel Russell-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Xiaoping Liang-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Yunxiang Zhang-24556.pdf
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML.ts
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Guillaume Richard-Carpentier-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Harinder Gill-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Leo Ruhnke-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Musa Yilmaz-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Naval Daver-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Sylvain Garciaz-24558.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents.ts
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Elias Jabbour-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Ghayas Issa-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Li Yang-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Robert Zeiser-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Sara Zarnegar-Lumley-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Yuchen Liu-24559.pdf
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Eduardo Magalhaes-24564.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Fanny Gonzales-24564.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Nastassja Scheidegger-24564.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Ramprasad Ramakrishnan-24564.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics V‚ronique Lisi-24564.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Andrew Stiff-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Diego Pereira-Martins-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Francisco Marchi-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Juan Barajas-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Martina Pigazzi-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Yotaro Ochi-24561.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Bettina Nadorp-24562.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Danielle Kirkey-24562.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Isabel Weinhaeuser-24562.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Sergio Rutella-24562.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Chong Chyn Chua-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Corentin Orvain-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Gege Gui-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jacqueline Cook-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jad Othman-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Maddalena Benetton-24563.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Adrian Mosquera Orgueira-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Curtis Lachowiez-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Mark Levis-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Pierre Peterlin-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Romane Joudinaud-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Shai Shimony-24560.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant.ts
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Adriane Halik-24565.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Gregor Hoermann-24565.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Hussein Abbas-24565.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Sander Lambo-24565.pdf
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response.ts
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Hanna Thorsson-24566.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Ilaria Iacobucci-24566.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Jingliao Zhang-24566.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Lorenz Bastian-24566.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Shunsuke Kimura-24566.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis.ts
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Anna Gurevich Shapiro-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Francesco Corrado-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Guranda Chitadze-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Satoshi Yoshimura-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Sean Tracy-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Willem Cox-24567.pdf
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment.ts
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alan Cooper-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alicia Beyou-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Andrew Feldman-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics James Phelan-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Natasha Lewis-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Sandrine Roulland-24568.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics.ts
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Alexis Claudel-24569.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Fabrice Jardin-24569.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Julia Paczkowska-24569.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Kyoko Yamaguchi-24569.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Tomohiro Aoki-24569.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc.ts
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Joseph Schroers-Martin-24570.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Pantaleo De Simone-24570.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Reid Merryman-24570.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Wen-Hsuan Wendy Lin-24570.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Xiyue Xu-24570.pdf
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma.ts
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Dylan Tatterton-24573.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jon Arnason-24573.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jose A. Martinez-Climent-24573.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Ken Young-24573.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Yusuke Isshiki-24573.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma.ts
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Ilja Kalashnikov-24572.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Kanutte Huse-24572.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Matias Autio-24572.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Vignesh Shanmugam-24572.pdf
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma.ts
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Franck Morschhauser-24574.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Jonathan Friedberg-24574.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Lorenzo Falchi-24574.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Stephen Schuster-24574.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy.ts
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emanuele Zucca-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emmanuel Bachy-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Jillian Gunther-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Loic Ysebaert-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Morgane Cheminant-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Yucai Wang-24577.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL.ts
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Anita Kumar-24576.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Carlo Visco-24576.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Craig Portell-24576.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Eliza Hawkes-24576.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Michael Wang-24576.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents.ts
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Clementine Sarkozy-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Jonathon Cohen-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Juan Alderuccio-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Paolo Strati-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Umberto Vitolo-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Vincent Ribrag-24575.pdf
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy.ts
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Catherine Diefenbach-24580.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Elizabeth Phillips-24580.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Hun Lee-24580.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Jeremy Abramson-24580.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma.ts
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Eric Jacobsen-24578.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Seok Jin Kim-24578.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Steven Horwitz-24578.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Yuqin Song-24578.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas.ts
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Alison Moskowitz-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Jonathan Brammer-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Pierluigi Porcu-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sanjal Desai-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sarah Rutherford-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Thais Fischer-24579.pdf
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas.ts
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Adam Olszewski-24582.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Clementine Sarkozy-24582.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jason Westin-24582.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jillian Simard-24582.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Lorenzo Falchi-24582.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas.ts
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Charalambos Andreadis-24583.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Christopher Melani-24583.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Gerhard Held-24583.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Martin Hutchings-24583.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Sabarish Ayyappan-24583.pdf
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Chan Cheah-24584.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Elizabeth Lihua Budde-24584.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Emil Kyvsgaard-24584.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Peter Riedell-24584.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Trent Wang-24584.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jelena Jelicic-24585.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jinhua Liang-24585.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jordan Goldstein-24585.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Mark Roschewski-24585.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Norbert Schmitz-24585.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Aung Tun-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Gloria Iacoboni-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Jean Koff-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Loretta Nastoupil-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Sanjal Desai-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Viktoriya Zelikson-24588.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Arushi Khurana-24589.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Brian Sworder-24589.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Fabian Frontzek-24589.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Pallawi Torka-24589.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Steven Bair-24589.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Andrew Zelenetz-24586.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Rena Buckstein-24586.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Shinpei Harada-24586.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient.ts
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Bhausaheb Bagal-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL David Hodgson-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Evelyn Orlando-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Kathryn Lurain-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Monica Balzarotti-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Steven Durani-24587.pdf
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL.ts
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jennifer O Sullivan-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jyoti Nangalia-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Marc Usart-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Matthew Stubbs-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Vignir Helgason-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Yuki Tahira-24591.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery.ts
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Billy Truong-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Charlotte Brierley-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Joseph Kim-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Molly Brakhane-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Nicole Vincelette-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Tim Kong-24590.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models.ts
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Golam Mohi-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Isabelle Becker-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Koki Ueda-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Madeline Caduc-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Naseer Basma-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Warren Fiskus-24592.pdf
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context.ts
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches David Yeung-24593.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Fadi Haddad-24593.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Jorge Cortes-24593.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Qian Jiang-24593.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Timothy Hughes-24593.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches.ts
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Andreas Hochhaus-24594.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Franck Nicolini-24594.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Frederic Millot-24594.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Susan Branford-24594.pdf
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication.ts
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Harinder Gill-24595.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Naveen Pemmaraju-24595.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Sanjay Mohan-24595.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Srinivas Tantravahi-24595.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Steffen Koschmieder-24595.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies.ts
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Lindsay Rein-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Nico Gagelmann-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Pankit Vachhani-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Raajit Rampal-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Rithin Nedumannil-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Yu-Hung Wang-24597.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers.ts
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Andrew Kuykendall-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Elliot Stieglitz-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Matthieu Groh-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Prithviraj Bose-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Sudipto Mukherjee-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Tsewang Tashi-24598.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies.ts
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Deepika Dilip-24596.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Ellen Ritchie-24596.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Joachim Goethert-24596.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Justin Watts-24596.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Trine Knudsen-24596.pdf
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs.ts
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Carmelo Gurnari-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications He Tian (Tony) Chen-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Martina Sarchi-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Noah Salama-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Srinivas Aluri-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Zohar Sachs-24599.pdf
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications.ts
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Elsa Bernard-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Johann-Christoph Jann-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Julia Montoro-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Luca Lanino-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Rurika Okuda-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Tariq Kewan-24600.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS.ts
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Cristina Astrid Tentori-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Guillermo Garcia-Manero-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Maria Diez-Campelo-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Moshe Mittelman-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Rami Komrokji-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Sandra Huber-24603.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS.ts
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Daniel Nguyen-24601.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Douglas Tremblay-24601.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jacqueline Garcia-24601.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jan Philipp Bewersdorf-24601.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Lok Lam Ngai-24601.pdf
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS.ts
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Billy Jebaraj-24604.pdf
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Claudio Martines-24604.pdf
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Laura Polcik-24604.pdf
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Prajish Iyer-24604.pdf
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Yi Miao-24604.pdf
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation.ts
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Armin Riecke-24606.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Jennifer Brown-24606.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Moritz Furstenau-24606.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Othman Al-Sawaf-24606.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Sarka Pavlova-24606.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation.ts
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Andy Rawstron-24605.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Carol Follows-24605.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Jeff Sharman-24605.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Paolo Ghia-24605.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Peter Hillmen-24605.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia.ts
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Constantine Tam-24607.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Brown-24607.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Woyach-24607.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Parag Jasani-24607.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Tanya Siddiqi-24607.pdf
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Georgina Anderson-24613.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Laura Lucia Cogrossi-24613.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Luz Moreno Rueda-24613.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Yakinthi Chrisochoidou-24613.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Zachary Hunter-24613.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Elizabeth Lightbody-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Faith Davies-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Hsiling Chiu-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Ross Firestone-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Takahiro Kamiya-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Xiaoli Mi-24608.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Deeksha Vishwamitra-24610.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Fumou Sun-24610.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Mansour Poorebrahim-24610.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Maximilian Merz-24610.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Ram Pillarisetti-24610.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Eugenio Morelli-24609.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marcella Kaddoura-24609.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marios Papadimitriou-24609.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Rodger Tiedemann-24609.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Wataru Kuroki-24609.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Anthony Cirrincione-24612.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Camila Guerrero-24612.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Elizabeth Lightbody-24612.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Yubin Kang-24612.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions.ts
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Itziar Cenzano-24611.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Marc-Andrea Baertsch-24611.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Minghao Dang-24611.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Saurabh Zanwar-24611.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Visanu Wanchai-24611.pdf
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Alireza Tafazzol-24616.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Benjamin Diamond-24616.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Chunrui Li-24616.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Sahar Khan-24616.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Yeasung Lee-24616.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Carmen Gonzalez-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Elizabeth Hill-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Febe Smits-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Nizar Bahlis-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Tadeusz Kubicki-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Yael Cohen-24620.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Carolina Schinke-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Daniel Wong-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Evangelos Terpos-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Martin Kaiser-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Theresia Akhlaghi-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Wenqiang Deng-24618.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Chakra Chaulagain-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Cristina Perez-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Efstathios Kastritis-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Jon Thorir Oskarsson-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Michael Wysota-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Santiago Thibaud-24617.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc..ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Gaurav Agarwal-24615.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Nisha Joseph-24615.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Noemi Puig-24615.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Yered Pita-Juarez-24615.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Darren Pan-24614.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Doris Hansen-24614.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Elise Cellerin-24614.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Michel Delforge-24614.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Sridevi Rajeeve-24614.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma.ts
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Aintzane Zabaleta-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Danai Dima-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Darren Pan-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Junia Vieira dos Santos-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Michel Delforge-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Xiang Zhou-24619.pdf
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications.ts
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Ajai Chari-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Hang Quach-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Jeffrey Matous-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Paul Richardson-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Sumit Madan-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Wee-Joo Chng-24623.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma.ts
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Cyrille Touzeau-24622.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Maria-Victoria Mateos-24622.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Niels van de Donk-24622.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Ola Landgren-24622.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Omar Nadeem-24622.pdf
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma.ts
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Efstathios Kastritis-24624.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Jahanzaib Khwaja-24624.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Moshe Gatt-24624.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Thorir Einarsson Long-24624.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Xin Jiang-24624.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis.ts
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Mackenzie Maberry-24625.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Nickolas Tsakmaklis-24625.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Shayna Sarosiek-24625.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Szymon Szymura-24625.pdf
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders.ts
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Aditiya Rayasam-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Albert Yeh-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Chi Nguyen-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Dongchang Zhao-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Kristina Mott-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Marco Calafiore-24626.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome.ts
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Andri Leo Lemarquis-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution David Granadier-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Fathima Mohamed-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Katja Weinacht-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Kevin Quann-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Lee-Kai Sun-24627.pdf
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Jufang Chang-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Lydia Lee-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Meixian Huang-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Varsha Sundaresan-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Yusuke Ito-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Zhiliang Bai-24629.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Ivan Cohen-24628.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Jan Mueller-24628.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Mohammad Alhomoud-24628.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Hongwei Ren-24631.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Jingyu Xiang-24631.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Puneeth Guruprasad-24631.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers James Kuzich-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jay Daniels-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jort Van Der Schans-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Kathryn Cappell-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Mathew Angelos-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Zhenlong Li-24633.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Benjamin Goldenson-24630.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Catherine Danis-24630.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Corynn Kasap-24630.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Mylinh Bayle-24630.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Sergio Rutella-24630.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies.ts
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Janaki Manoja Vinnakota-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Ruchi Patel-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Shinpei Harada-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Stefanie Bachl-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Taisuke Kondo-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Yongxian HU-24632.pdf
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights.ts
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Aibin Liang-24634.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Jens Hillengass-24634.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Matthew Frigault-24634.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Nirav Shah-24634.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas.ts
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Anand Bhagwat-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Claire Roddie-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Elizabeth Lihua Budde-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Fabian Mueller-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Peihua Lu-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Susan Bal-24637.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies.ts
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Jae Park-24636.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Julio Chavez-24636.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Lei Yu-24636.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Pierre Sesques-24636.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Robert Weinkove-24636.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies.ts
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Arjan van de Loosdrecht-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Armin Ghobadi-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Jessica Liegel-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Nirali Shah-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Samer Srour-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Yago Nieto-24635.pdf
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas.ts
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Adam Kittai-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Alison Sehgal-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Andre Goy-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Jennifer Crombie-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Michael Cook-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Swetha Kambhampati-24638.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data.ts
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Anna Ossami Saidy-24639.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Evandro Bezerra-24639.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Gregory Roloff-24639.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Jay Spiegel-24639.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Surbhi Sidana-24639.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas.ts
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Kai Rejeski-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Karthik Nath-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Mark Hamilton-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Matthew Frigault-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Roni Shouval-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Zimu Gong-24640.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity.ts
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Ash Alizadeh-24641.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Gloria Iacoboni-24641.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Katie Maurer-24641.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Mike Mattie-24641.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Sandeep Raj-24641.pdf
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors.ts
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Daisuke Araki-24642.pdf
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Kate Markey-24642.pdf
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Laurent Garderet-24642.pdf
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Natalie Holl-24642.pdf
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Yi-Jiun Su-24642.pdf
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells.ts
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Amado Karduss-24644.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Biqi Zhou-24644.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Filippo Milano-24644.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Reem Alasbali-24644.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Simona Piemontese-24644.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool.ts
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Andrew Artz-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anita Lawitschka-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anthony Sabulski-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Eric Davis-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Madhavi Lakkaraja-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Michael Grimley-24643.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications.ts
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Arpita Gandhi-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hannah Choe-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hao Zheng-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Ibrahim Yakoub-Agha-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Marie Robin-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Xiaoyu Zhang-24646.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies.ts
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Bertram Glass-24645.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Caspian Oliai-24645.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Issa Khouri-24645.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Krzysztof Kalwak-24645.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Rajni Agarwal-24645.pdf
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia.ts
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Alina Markova-24647.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Jeffery Auletta-24647.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Nikolaos Spyrou-24647.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Yu Akahoshi-24647.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Zachariah Defilipp-24647.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management.ts
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Erik Thiele Orberg-24648.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Haowen Xiao-24648.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Leslie Kean-24648.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Michael Martens-24648.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Xiaoxuan Lai-24648.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology.ts
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Corey Cutler-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Hang Zhang-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Nicoletta Cieri-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Ramzi Abboud-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Robert Zeiser-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Zachariah Defilipp-24649.pdf
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment.ts
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Alexandria Maurer-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Dustin McCurry-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Hengwei Wu-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Luca Vago-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Nicoletta Cieri-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Shahinaz Gadalla-24651.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes.ts
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Arnon Nagler-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mary Eapen-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mazin Mohamed Abdulsalam-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Rohtesh Mehta-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Sitong Chen-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Zhihui Li-24650.pdf
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations.ts
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Gordon Cook-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach June-Wha Rhee-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Leyre Bento-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Marc-Andrea Baertsch-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Mazyar Shadman-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Shohei Mizuno-24652.pdf
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach.ts
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Arnon Nagler-24653.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Johannes Schetelig-24653.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Juan Montoro-24653.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Minoru Kanaya-24653.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Rohtesh Mehta-24653.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection.ts
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Ali Bazarbachi-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Shernan Holtan-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Simona Pagliuca-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Timothy Voorhees-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yuho Najima-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yves Chalandon-24655.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation.ts
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Ali Bazarbachi-24654.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Benjamin Huang-24654.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Iman Abou Dalle-24654.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Zaid Abdel Rahman-24654.pdf
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification.ts
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Alok Srivastava-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside John DiPersio-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Naoya Uchida-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Simon Chu-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Stefan Radtke-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Vincent Muczynski-24657.pdf
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside.ts
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Franco Locatelli-24656.pdf
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Haydar Frangoul-24656.pdf
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Julie Kanter-24656.pdf
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Steven Pipe-24656.pdf
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Ulrike Reiss-24656.pdf
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders.ts
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Anna Montanaro-24658.pdf
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Chao-Yie Yang-24658.pdf
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Lukas Kazianka-24658.pdf
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Monika Toma-24658.pdf
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Samuel Taylor-24658.pdf
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders.ts
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Arda Durmaz-24659.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Chorom Pak-24659.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Jurik Mutter-24659.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Yoonkyu Lee-24659.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology.ts
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Andrew Srisuwananukorn-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Anna Kamysheva-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Catherine Lecat-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Chen Zhou-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Gianluca Asti-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Yoko Kawamura-24660.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology.ts
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Francisco Marchi-24661.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Gianluca Asti-24661.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Jing Sun-24661.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Vikram Dhillon-24661.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Zhongxun Shi-24661.pdf
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology.ts
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Ashish Gupta-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Cecily Allen-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Costa Kazadi-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Lucy Fox-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Shiliang Ge-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Steven Hardy-24664.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology.ts
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Charles Jonassaint-24662.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Kim Smith-Whitley-24662.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Layla Van Doren-24662.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Pranav Shrestha-24662.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Robyn Cohen-24662.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education.ts
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Chiara Alessandra Cella-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Ming Y Lim-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Neha Bhasin-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Richard Godby-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Sara Mancuso-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Stacey Fedewa-24663.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders.ts
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Erica Mamauag-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ifeyinwa Osunkwo-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Julie Kanter-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ofelia Alvarez-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Wally Smith-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Yogindra Persaud-24665.pdf
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum.ts
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Aaron Cohen-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Arti Vaishnav-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Laura Quillen-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Mia Djulbegovic-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Pallavi Ganguli-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Sikander Ailawadhi-24666.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias.ts
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Atharva Karulkar-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Matthew Gromowsky-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Meng-Hsuan Lin-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Patrick Connor Johnson-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Radhika Bansal-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Tonya Cox-24668.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy.ts
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Andrew Hantel-24667.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Chieh Yang-24667.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Jing-Zhou Hou-24667.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Ludovic Fouillet-24667.pdf
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data.ts
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christa Meyer-24669.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christopher Su-24669.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Marissa Locastro-24669.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Pamela Egan-24669.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Thomas Walsh-24669.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies.ts
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Ashley Hadjis-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Christopher Strouse-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Danielle McQuinn-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Eshana Shah-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Jaime Preussler-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Rahul Mishra-24670.pdf
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies.ts
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Andrew Kuykendall-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jiasen He-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jordan Schaefer-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Josue Marquez-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Justine Ryu-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Ummul Asfeen-24672.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients.ts
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Charity Oyedeji-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Joseph Walden-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Kim Agrippa-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Oliver Shastri-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Rajagopalan Subramaniam-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Seethal Jacob-24671.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease.ts
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Antonio Risitano-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders George Goshua-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Nora Gibson-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Satoko Ito-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Shoshana Revel-Vilk-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Vincent Ho-24673.pdf
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma David Cordas dos Santos-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Francesco Marchesi-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Ghulam Rehman Mohyuddin-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Rahul Banerjee-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Roberto Mina-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Shakira Grant-24677.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Adam Kittai-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Amber Koehler-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Andres Noyola-Perez-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Maria Fernandez Turizo-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Rockbum Kim-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Vaishali Dulobdas-24678.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data David Leaf-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Kimberly Saverno-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Mazyar Shadman-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Narendranath Epperla-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Nilanjan Ghosh-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Pere Barba-24675.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Alissa Visram-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Doris Hansen-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Fieke Hoff-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Hira Mian-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Inger Nijhof-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Meera Mohan-24674.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Amy Wang-24676.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Annalynn Williams-24676.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Benoit Tessoulin-24676.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Guillaume Cartron-24676.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Timothy OConnor-24676.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies.ts
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Gin Yi Lee-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Jorge Florindez-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Kaitlin Annunzio-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Mustafa Wasifuddin-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Narendranath Epperla-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Niloufer Khan-24679.pdf
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma.ts
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Alice Mims-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Amer Zeidan-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Caitlin Elgarten-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Diego Adrianzen Herrera-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Emanuele Angelucci-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Nosakhare Ilerhunmwuwa-24682.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes.ts
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Alma Habib-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Daniel Zheng-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Jeffrey Rubnitz-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michael Grunwald-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michelle Lee-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Teresa Caprice-24681.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities.ts
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Areej El-Jawahri-24680.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Diego Adrianzen Herrera-24680.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Esther Oliva-24680.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Kirollos Hanna-24680.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Valeria Santini-24680.pdf
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies.ts
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Linde Miles-24146.pdf
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Mark Dawson-24146.pdf
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Seishi Ogawa-24146.pdf
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies.ts
Scientific Program Emerging Methodologies to Investigate Platelet Biology Andrew Johnson-24144.pdf
Scientific Program Emerging Methodologies to Investigate Platelet Biology Anita Eckly-24144.pdf
Scientific Program Emerging Methodologies to Investigate Platelet Biology Florian Gaertner-24144.pdf
Scientific Program Emerging Methodologies to Investigate Platelet Biology.ts
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Demin Wang-24150.pdf
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Rick Kapur-24150.pdf
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Satheesh Chonat-24150.pdf
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine.ts
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Dachuan Zhang-24143.pdf
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Leon Kautz-24143.pdf
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis.ts
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Alexander Marson-24142.pdf
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Carl June-24142.pdf
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Chiara Bonini-24142.pdf
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Dan Kaufman-24142.pdf
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy.ts
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Aswin Sekar-24139.pdf
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Laura Pasqualucci-24139.pdf
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Mandeep Singh-24139.pdf
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies.ts
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Alan Cantor-24145.pdf
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Anna Beaudin-24145.pdf
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Shannon McKinney-Freeman-24145.pdf
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood.ts
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Alyssa Kennedy-24137.pdf
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Jean Soulier-24137.pdf
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Sushree Sahoo-24137.pdf
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes.ts
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Evi Stavrou-24149.pdf
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Ioannis Mitroulis-24149.pdf
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Kimberly Martinod-24149.pdf
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis.ts
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Jeroen Eikenboom-24141.pdf
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Leah Sabin-24141.pdf
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Lindsey George-24141.pdf
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders.ts
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Jordan Shavit-24136.pdf
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Pavel Davizon-Castillo-24136.pdf
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Suzan Williams-24136.pdf
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome.ts
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Daniel Lucas-Alcaraz-24140.pdf
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Maria Carolina Florian-24140.pdf
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Tiago Luis-24140.pdf
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis.ts
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Elham Azizi-24138.pdf
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Fei Chen-24138.pdf
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Rong Fan-24138.pdf
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology.ts
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Eugenio Morelli-24147.pdf
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Marta Chesi-24147.pdf
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Tom Cupedo-24147.pdf
Scientific Program The Evolution of Multiple Myeloma From Inside-Out.ts
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Ann Dean-24148.pdf
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Gerd Blobel-24148.pdf
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Mitchell Weiss-24148.pdf
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.ts
Scientific Symposia Alternative Immune Effector Cells Evan Weber-24835.pdf
Scientific Symposia Alternative Immune Effector Cells James Cronk-24835.pdf
Scientific Symposia Alternative Immune Effector Cells Marie Bleakley-24835.pdf
Scientific Symposia Alternative Immune Effector Cells.ts
Scientific Symposia Multi-Omics Driven Precision Hematology Jun J. Yang-24836.pdf
Scientific Symposia Multi-Omics Driven Precision Hematology Mika Kontro-24836.pdf
Scientific Symposia Multi-Omics Driven Precision Hematology Pamela Becker-24836.pdf
Scientific Symposia Multi-Omics Driven Precision Hematology.ts
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Caterina Casari-24833.pdf
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Matthew Flick-24833.pdf
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis.ts
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Ami Smith-24834.pdf
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Kate Markey-24834.pdf
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Marcel van den Brink-24834.pdf
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies.ts
Scientific Symposia Understanding Sickle Cell Pathophysiology Enrico Novelli-24837.pdf
Scientific Symposia Understanding Sickle Cell Pathophysiology Jeffrey Chalmers-24837.pdf
Scientific Symposia Understanding Sickle Cell Pathophysiology Lucia De Franceschi-24837.pdf
Scientific Symposia Understanding Sickle Cell Pathophysiology.ts
Special-Interest Sessions 2023 ASH Guideline Implementation Champions Christina Ruiz-24365.pdf
Special-Interest Sessions 2023 ASH Guideline Implementation Champions Gabriella Nguyen-24365.pdf
Special-Interest Sessions 2023 ASH Guideline Implementation Champions.ts
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Torsten Haferlach-24388.pdf
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Weida Tong-24388.pdf
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Yates Coley-24388.pdf
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023.ts
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Alessandra Ferrajoli-24366.pdf
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Ayman Alhejazi-24366.pdf
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Vilmarie Rodriguez-24366.pdf
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions.ts
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Aaron Goodman-24159.pdf
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Benjamin Tillman-24159.pdf
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients David Andorsky-24159.pdf
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Shannon Walker-24159.pdf
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients.ts
Special-Interest Sessions ASH Grassroots Network Lunch.ts
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Julie Wolfson-24153.pdf
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Sumit Gupta-24153.pdf
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Wendy Stock-24153.pdf
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults.ts
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Deborah Siegal-24152.pdf
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Saskia Middeldorp-24152.pdf
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Suely Rezende-24152.pdf
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New.ts
Special-Interest Sessions Blood and Beyond.ts
Special-Interest Sessions Junior Faculty Career Development Session Cassandra Josephson-24155.pdf
Special-Interest Sessions Junior Faculty Career Development Session Oyebimpe Adesina-24155.pdf
Special-Interest Sessions Junior Faculty Career Development Session Srinivas Devarakonda-24155.pdf
Special-Interest Sessions Junior Faculty Career Development Session.ts
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Alison Loren-24158.pdf
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Erica Marsh-24158.pdf
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Mindy Christianson-24158.pdf
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care.ts
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Alisa Wolberg-24154.pdf
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Nicole Gormley-24154.pdf
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Saad Usmani-24154.pdf
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community.ts
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Alexis Leonard-24422.pdf
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Julie Kanter-24422.pdf
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Sophie Lanzkron-24422.pdf
Special-Interest Sessions Special Session on Sickle Cell Disease Centers.ts
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Alexandra Power-Hays-24151.pdf
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Allison Burnett-24151.pdf
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Geoffrey Barnes-24151.pdf
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care.ts
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Sandhya Panch-24367.pdf
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Surbhi Shah-24367.pdf
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation.ts
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ludmila Prokunina-Olsson-24831.pdf
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ryan Morin-24831.pdf
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma.ts
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Deborah Siegal-24130.pdf
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Sam Schulman-24130.pdf
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors.ts
Spotlight Sessions Immunometabolism as a Tool to Advance Cell Therapy.ts
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Paolo Ghia-24131.pdf
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Zhuoer Xie-24131.pdf
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL.ts
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Srinivas Devarakonda-24830.pdf
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Yvonne Efebera-24830.pdf
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients.ts
Spotlight Sessions The Mysteries of Factor XI David Gailani-24832.pdf
Spotlight Sessions The Mysteries of Factor XI Ophira Salomon-24832.pdf
Spotlight Sessions The Mysteries of Factor XI.ts
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution John Mark Sloan-24128.pdf
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Lauren Merz-24128.pdf
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution.ts
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Justin Taylor-24132.pdf
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Valeria Santini-24132.pdf
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials.ts
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Carlos Ramos-24129.pdf
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Jonathan Fisher-24129.pdf
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes.ts
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Amber Yates-24862.pdf
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Timothy Kubal-24862.pdf
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia.ts
Trainee Didactic Session Show Me the Money – Funding Your Research Cassandra Josephson-24865.pdf
Trainee Didactic Session Show Me the Money – Funding Your Research Ifeyinwa Osunkwo-24865.pdf
Trainee Didactic Session Show Me the Money – Funding Your Research.ts
Trainee Didactic Session The International Trainee Journey Andres Gomez-De Leon-24160.pdf
Trainee Didactic Session The International Trainee Journey Eloisa Riva-24160.pdf
Trainee Didactic Session The International Trainee Journey.ts
Trainee Didactic Session What to Ask For in an Interview Alison Walker-24867.pdf
Trainee Didactic Session What to Ask For in an Interview.ts